Mera-med.ru

Онкология
- Лечение онкологии
- Меланома
- Лейкоз
- Острый лейкоз
- Хронический лейкоз
- Лейкоз крови
- Рак



















онколог офтальмолог

Unresolved there is a question on optimum duration of chemotherapy of the first line. Today it is possible to recommend an individual approach in each concrete case. At a stage of chemotherapy of the first line it is necessary to aspire to achievement of full regress with disappearance of all displays of illness including normalization of level СА-125, and then to fix the achieved effect carrying out of 2-3 more additional rates. At achievement of partial regress it is necessary to continue chemotherapy till the moment when during two last rates stabilization of illness is marked, estimating on the sizes of residual tumoral weights and concentration of tumoral markers. By own experience I can tell, that in these cases at the majority of patients the number of courses of treatment will make from 6 up to 12, but not less than 6. In case of stabilization of illness it is necessary to limit volume of treatment by 6 rates after which end therapy can be stopped up to attributes of progressing or it is continued with use of modes of the second line depending on the general{common} condition of the patient and its{her} attitude{relation} to the further carrying out chemotherapy. At progressing illness it is necessary to pass to modes of the second line of chemotherapy. Подробнее...

Break of a ring molecule virus ДНК can occur in any place, however most frequently - in area Е1/Е2; exception is area URR-Е6-Е7, which интактна as in морфологически not changed эпителии and at дисплазиях, and in tumoral cells{cages}. Disappearance супрессорной causes functions of virus fiber Е2 суперэкспрессию virus онкогенов Е6-Е7, трансформирующее which action promotes a progression неоплазий. It is supposed, that gene Е1 participates in suppression of the virus promotor, consequence{investigation} of a mutation of gene Е1 are activation of a transcription virus генома and increase трансформирующей activity virus онкогенов [16,23]. Подробнее...